Insider Buying: Rallybio (NASDAQ:RLYB) Major Shareholder Acquires $84,005.82 in Stock

Rallybio Corporation (NASDAQ:RLYB) major shareholder Adar1 Capital Management, Llc acquired 6,009 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The stock was bought at an average price of $13.98 per share, with a total value of $84,005.82. Following the acquisition, the insider directly owned 916,152 shares of the company’s stock, valued at $12,807,804.96. The trade was a 0.66% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

• On Tuesday, May 19th, Adar1 Capital Management, Llc acquired 10,200 shares of Rallybio stock. The stock was bought at an average price of $13.98 per share, with a total value of $142,596.00.
• On Friday, May 15th, Adar1 Capital Management, Llc acquired 300 shares of Rallybio stock. The stock was bought at an average price of $13.90 per share, with a total value of $4,170.00.
• On Wednesday, May 13th, Adar1 Capital Management, Llc purchased 79,259 shares of Rallybio stock. The stock was acquired at an average price of $13.99 per share, with a total value of $1,108,833.41.
• On Tuesday, May 12th, Adar1 Capital Management, Llc purchased 800 shares of Rallybio stock. The stock was acquired at an average price of $13.83 per share, with a total value of $11,064.00.
• On Monday, May 11th, Adar1 Capital Management, Llc purchased 50,000 shares of Rallybio stock. The stock was acquired at an average price of $14.00 per share, with a total value of $700,000.00.
• On Tuesday, May 5th, Adar1 Capital Management, Llc purchased 35,101 shares of Rallybio stock. The stock was acquired at an average price of $14.00 per share, with a total value of $491,414.00.
• On Monday, May 4th, Adar1 Capital Management, Llc acquired 120,804 shares of Rallybio stock. The shares were purchased at an average cost of $13.97 per share, with a total value of $1,687,631.88.

Rallybio Price Performance

RLYB stock opened at $15.88 on Friday. The stock has a market capitalization of $84.16 million, a P/E ratio of -3.66 and a beta of -1.10. The business has a 50-day moving average of $10.28 and a 200-day moving average of $7.38. Rallybio Corporation has a fifty-two week low of $2.16 and a fifty-two week high of $16.00.

Rallybio (NASDAQ:RLYB) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.26). Rallybio had a negative return on equity of 55.79% and a negative net margin of 911.07%.The firm had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.21 million.

Wall Street Analysts Forecast Growth

RLYB has been the subject of a number of recent analyst reports. Wall Street Zen raised Rallybio to a “hold” rating in a research report on Saturday, March 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rallybio in a research note on Friday, May 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

Institutional Investors Weigh In On Rallybio

Several hedge funds have recently modified their holdings of RLYB. Renaissance Technologies LLC lifted its holdings in Rallybio by 16.9% during the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock worth $573,000 after buying an additional 120,892 shares during the period. Geode Capital Management LLC lifted its holdings in Rallybio by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after buying an additional 2,996 shares during the period. Citadel Advisors LLC lifted its holdings in Rallybio by 576.1% during the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock worth $219,000 after buying an additional 373,821 shares during the period. Susquehanna International Group LLP lifted its holdings in Rallybio by 485.9% during the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after buying an additional 113,031 shares during the period. Finally, XTX Topco Ltd lifted its holdings in Rallybio by 64.6% during the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock worth $67,000 after buying an additional 38,205 shares during the period. Institutional investors and hedge funds own 90.34% of the company’s stock.

About Rallybio

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.